GPCR press release
RTPR•19/10/2026•16:13 ET
0
Key Highlights
- ➤Structure Therapeutics will present two aleniglipron obesity trial posters at ObesityWeek®
- ➤Aleniglipron is an investigational once-daily oral small-molecule GLP-1 receptor agonist
- ➤Presentations cover ACCESS open-label extension and dose-ranging trial effects
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD.
Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension Date/Time: November 15, 2026, 2:30 p.m. – 3:30 p.m. ET Location: Exhibit Hall BCD
Get started
Create a free account to read the full story.